Celecoxib and rofecoxib equally effective in knee OA

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1303, 2001-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost effectiveness of celecoxib, rofecoxib in OA and RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 352, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cost effectiveness of celecoxib, rofecoxib in OA and RA

Inpharma, Vol. 1, Iss. 1327, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Glucosamine cost effective for primary knee OA in France

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 606, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Direct-to-consumer (DTC) advertising of rofecoxib [Vioxx] and celecoxib [Celebrex] increased the number of patients with osteoarthritis (OA) seen by physicians each month

Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Direct-to-consumer (DTC) advertising of rofecoxib [Vioxx] and celecoxib [Celebrex] increased the number of patients with osteoarthritis (OA) seen by physicians each month

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 519, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite